Maravai LifeSciences Holdings Inc. Class A Common Stock vs Advanced Drainage Systems Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Advanced Drainage Systems Inc trades at $125.03 (market cap $9.56B). The key difference: Advanced Drainage Systems Inc is far larger — about 9.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Advanced Drainage Systems Inc for 43 Days on average.
| MRVI | WMS | |
|---|---|---|
Market Cap | $972.90M | $9.56B |
Volume | 4,325,710 | 716,757 |
Sector | Health | Basic Materials |
52-Week High | $9.00 | $175.38 |
52-Week Low | $2.83 | $125.19 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $1.08B | $11.16B |
Dividend Yield | — | 0.63% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Advanced Drainage Systems (WMS) trades at $125.19, down 0.59% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.49 beating estimates of $2.10. Revenue remains stable at $2.90B for 2025, while profitability metrics show robust ROE of 24.9% and net margin of 14%. Recent news highlights institutional buying activity and the release of Q1 2027 results showing 21% revenue growth.
WMS presents a compelling investment case with strong fundamentals and analyst consensus pointing to significant upside potential (target $188.20). However, near-term technical weakness and projected negative cash flow in 2026 warrant caution. The stock offers exposure to water infrastructure growth but faces execution risks from recent acquisitions and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →